Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02300610 · ClinicalTrials.gov registry record · Phase 1
Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer
A Phase 1 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT02300610 is a Phase 1 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 10 participants.
The verdict
NCT02300610, a Phase 1 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The main purpose of this study is to find out the dose of enzalutamide that can be safely given with gemcitabine and cisplatin in patients with advanced bladder cancer. Researchers also want to find out the side effects of these drugs when given together. This study will also help in finding out the effect on tumor of the combination of enzalutamide, gemcitabine and cisplatin.
Interventions
- DRUG Cisplatin
- DRUG Gemcitabine
- DRUG Enzalutamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2015-02-11 |
| Est. Completion | 2019-04-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02300610
The ClinicalTrials.gov registry entry for NCT02300610 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cisplatin is the first listed.
NCT02300610 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02300610 about?
NCT02300610 is a clinical study titled "Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer". The main purpose of this study is to find out the dose of enzalutamide that can be safely given with gemcitabine and cisplatin in patients with advanced bladder cancer. Researchers also want to find out the side effects of these drugs when given together. This study will also help in finding out the...
What is the current status of trial NCT02300610?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2015-02-11. Estimated completion is 2019-04-19.
What interventions are being tested in trial NCT02300610?
The interventions under investigation include: Cisplatin (DRUG), Gemcitabine (DRUG), Enzalutamide (DRUG).
Who is sponsoring clinical trial NCT02300610?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.